
Quarterly report 2024-Q2
added 08-07-2024
Alimera Sciences Net Debt 2011-2025 | ALIM
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.2 M | -4.38 M | -16.1 M | 32.7 M | 30 M | 25.4 M | 10.7 M | 2.57 M | 1.53 M | -42.6 M | -7.77 M | -46.6 M | -27.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.7 M | -46.6 M | -4.11 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Assertio Holdings
ASRT
|
-34 M | $ 0.66 | -0.02 % | $ 46.9 M | ||
|
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
193 M | $ 1.31 | -6.43 % | $ 141 M | ||
|
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | ||
|
Cronos Group
CRON
|
-1.07 B | $ 2.74 | -0.36 % | $ 1.44 B | ||
|
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
285 M | $ 4.57 | -1.72 % | $ 86.3 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
338 M | $ 12.63 | 0.72 % | $ 647 M | ||
|
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | $ 21.58 | 0.19 % | $ 2.05 B | ||
|
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | ||
|
Evolus
EOLS
|
36.3 M | $ 6.85 | 0.59 % | $ 425 M | ||
|
Harrow Health
HROW
|
173 M | $ 50.16 | 2.05 % | $ 1.64 B | ||
|
China Pharma Holdings
CPHI
|
-4.73 M | $ 1.31 | -1.5 % | $ 22.9 M | ||
|
Organogenesis Holdings
ORGO
|
-131 M | $ 5.87 | 2.09 % | $ 773 M | ||
|
Pacira BioSciences
PCRX
|
317 M | $ 26.02 | 1.09 % | $ 1.2 B | ||
|
Bausch Health Companies
BHC
|
21.1 B | $ 7.18 | -1.91 % | $ 2.62 B | ||
|
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
90.7 M | $ 1.76 | 1.15 % | $ 402 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 4.2 | -1.41 % | $ 59.1 M | ||
|
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | ||
|
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-2.5 M | $ 4.6 | 2.45 % | $ 138 M | ||
|
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | ||
|
Rockwell Medical
RMTI
|
691 K | $ 0.81 | -0.81 % | $ 18.9 M | ||
|
Perrigo Company plc
PRGO
|
3.05 B | $ 13.75 | 0.51 % | $ 1.89 B | ||
|
ProPhase Labs
PRPH
|
-6.41 M | $ 0.62 | -10.48 % | $ 9.82 M | ||
|
Sundial Growers
SNDL
|
-28.4 M | $ 1.77 | -0.56 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | ||
|
Solid Biosciences
SLDB
|
-70.9 M | $ 5.9 | - | $ 241 M | ||
|
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 3.64 | 1.68 % | $ 4.52 M | ||
|
SCYNEXIS
SCYX
|
-31.1 M | $ 0.6 | 1.78 % | $ 28.7 M | ||
|
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
14.4 M | $ 10.15 | -3.61 % | $ 6.27 B | ||
|
TherapeuticsMD
TXMD
|
3.68 M | $ 1.7 | 3.66 % | $ 17.7 M | ||
|
Veru
VERU
|
-20.9 M | $ 2.34 | 0.86 % | $ 316 M | ||
|
cbdMD
YCBD
|
-521 K | $ 1.59 | -4.22 % | $ 6.86 M | ||
|
Viatris
VTRS
|
16.8 B | $ 12.24 | 1.83 % | $ 14.8 B | ||
|
Zomedica Corp.
ZOM
|
-10.2 M | - | -0.21 % | $ 98 M |